Extracorporeal Membrane Oxygenation to Support Life-Threatening Drug-Refractory Electrical Storm.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 17 8 2020
medline: 26 5 2021
entrez: 16 8 2020
Statut: ppublish

Résumé

Despite rapid implementation of anti-arrhythmic treatment and sedation and controlling the triggering event, rare patients develop treatment-refractory electrical storm and their hemodynamic instability prevents emergency catheter ablation. In that context, venoarterial extracorporeal membrane oxygenation could rapidly restore hemodynamics and tissue perfusion and reduce myocardial oxygen consumption, until adequate anti-arrhythmic drug levels are reached to safely perform catheter ablation. Retrospective, multicenter study over an 8-year period. Two French tertiary care centers. Eighty-three consecutive adults with venoarterial extracorporeal membrane oxygenation-supported treatment-refractory electrical storm (median [interquartile range] age, 55 yr [48-63 yr]). Fifty-nine percent of these patients had acute ischemic cardiomyopathy and 66% underwent cardiopulmonary resuscitation prior to venoarterial extracorporeal membrane oxygenation initiation, with 18% cannulated during it. Fifty patients (60%) had ventricular tachycardia and/or ventricular fibrillation alternating with short periods of sinus rhythm and 33 (40%) had refractory ventricular tachycardia and/or ventricular fibrillation. Twelve patients (15%) underwent safe catheter ablation under venoarterial extracorporeal membrane oxygenation. After a median of 3 days (1-13 d) on extracorporeal membrane oxygenation support, 37 patients (45%) were successfully weaned off and 42% were alive 6 months post-ICU admission. Multivariable analysis retained ventricular tachycardia and/or ventricular fibrillation episodes alternating with short periods of sinus rhythm (odds ratio, 0.18; 95% CI, 0.06-0.52; p = 0.002) and age less than 50 years (odds ratio, 0.32; 95% CI, 0.18-0.89; p = 0.002) as being independent protective factors with 6-month survival, regardless of the underlying electrical storm cause. Among venoarterial extracorporeal membrane oxygenation-supported drug-refractory electrical storm patients, 42% survived 6 months post-ICU admission. Ventricular tachycardia and/or ventricular fibrillation episodes alternating with short periods of sinus rhythm and age less than 50 years were independently associated with better survival.

Identifiants

pubmed: 32796185
doi: 10.1097/CCM.0000000000004490
pii: 00003246-202010000-00028
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e856-e863

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Références

Gao D, Sapp JL. Electrical storm: Definitions, clinical importance, and treatment. Curr Opin Cardiol 2013; 28:72–79
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.; ESC Scientific Document Group: 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36:2793–2867
Tsuji Y, Heijman J, Nattel S, et al. Electrical storm: Recent pathophysiological insights and therapeutic consequences. Basic Res Cardiol 2013; 108:336
Guerra F, Shkoza M, Scappini L, et al. Role of electrical storm as a mortality and morbidity risk factor and its clinical predictors: A meta-analysis. Europace 2014; 16:347–353
Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol 2014; 63:2769–2778
Baratto F, Pappalardo F, Oloriz T, et al. Extracorporeal membrane oxygenation for hemodynamic support of ventricular tachycardia ablation. Circ Arrhythm Electrophysiol 2016; 9:e004492
Le Pennec-Prigent S, Flecher E, Auffret V, et al. Effectiveness of extracorporeal life support for patients with cardiogenic shock due to intractable arrhythmic storm. Crit Care Med 2017; 45:e281–e289
Combes A, Leprince P, Luyt CE, et al. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 2008; 36:1404–1411
Danial P, Hajage D, Nguyen LS, et al. Percutaneous versus surgical femoro-femoral veno-arterial ECMO: A propensity score matched study. Intensive Care Med 2018; 44:2153–2161
GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med1993; 329:1615–1622
Mehran R, Steg PG, White HD, et al. Letter by Mehran et al regarding article, “Bleeding academic research consortium consensus report: the food and drug administration perspective.” Circulation 2012; 125:e460
Fux T, Svenarud P, Grinnemo KH, et al. Extracorporeal membrane oxygenation as a rescue of intractable ventricular fibrillation and bridge to heart transplantation. Eur J Heart Fail 2010; 12:301–304
Pagel PS, Lilly RE, Nicolosi AC. Use of ECMO to temporize circulatory instability during severe Brugada electrical storm. Ann Thorac Surg 2009; 88:982–983
Hu W, Chen L, Liu C, et al. Three cases of electrical storm in fulminant myocarditis treated by extracorporeal membrane oxygenation. Am J Emerg Med 2015; 33:606.e3–e8
Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: The survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J 2015; 36:2246–2256
Richardson AS, Schmidt M, Bailey M, et al. ECMO Cardio-Pulmonary Resuscitation (ECPR), trends in survival from an international multicentre cohort study over 12-years. Resuscitation 2017; 112:34–40
Barbaro RP, Odetola FO, Kidwell KM, et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med 2015; 191:894–901
Muller G, Flecher E, Lebreton G, et al. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med 2016; 42:370–378
Thiele H, Zeymer U, Neumann FJ, et al.; IABP-SHOCK II Trial Investigators: Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287–1296
Thiele H, Zeymer U, Thelemann N, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: Long-term 6-year outcome of the randomized IABP-SHOCK II trial. Circulation 2019; 139:395–403

Auteurs

Guillaume Baudry (G)

Heart Failure Unit, Hospices Civils de Lyon, Louis Pradel Hospital, Bron, France.
Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Romain Sonneville (R)

Université de Paris, INSERM UMR1148, team 6, Paris, France.
Médecine Intensive-Réanimation, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France.

Xavier Waintraub (X)

Electrophysiology Unit, Cardiology Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Guillaume Lebreton (G)

Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
Department of Cardiovascular and Thoracic Surgery, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Camille Deguillard (C)

Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Emilie Mertens (E)

Médecine Intensive-Réanimation, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France.

Lila Bouadma (L)

Université de Paris, INSERM UMR1148, team 6, Paris, France.
Médecine Intensive-Réanimation, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France.

Pierre Demondion (P)

Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
Department of Cardiovascular and Thoracic Surgery, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Nicolas Bréchot (N)

Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Charles-Edouard Luyt (CE)

Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Fabrice Extramiana (F)

Unité de Rythmologie, Centre de Référence Maladies Cardiaques Héréditaires, Service de Cardiologie, Université de Paris, AP-HP Hôpital Bichat, 46, rue Henri- Huchard, Paris, France.

Guillaume Hékimian (G)

Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Claire Dupuis (C)

Université de Paris, INSERM UMR1148, team 6, Paris, France.
Médecine Intensive-Réanimation, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France.

Marylou Para (M)

Department of Cardiovascular and Thoracic Surgery, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Paris, France.

Angelo Pisani (A)

Department of Cardiovascular and Thoracic Surgery, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Paris, France.

Wael Braham (W)

Department of Cardiovascular and Thoracic Surgery, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Paris, France.

Estelle Gandjbakhch (E)

Electrophysiology Unit, Cardiology Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Antoine Leenhardt (A)

Unité de Rythmologie, Centre de Référence Maladies Cardiaques Héréditaires, Service de Cardiologie, Université de Paris, AP-HP Hôpital Bichat, 46, rue Henri- Huchard, Paris, France.

Jean-François Timsit (JF)

Université de Paris, INSERM UMR1148, team 6, Paris, France.
Médecine Intensive-Réanimation, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France.

Pascal Leprince (P)

Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
Department of Cardiovascular and Thoracic Surgery, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Alain Combes (A)

Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Matthieu Schmidt (M)

Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH